Repeated Neurocognitive Measurements in Depressed Patients

Depression, Unipolar Clinical Trial

Official title:

Repeated Neurocognitive Measurements in Depressed Patients

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT04916548
• Other study ID #: STUDY21040075
• Status: Completed
• Phase: Phase 1/Phase 2
• Start date: September 16, 2021
• Est. completion date: August 15, 2023

Study information

• Verified date: September 2023
• Source: University of Pittsburgh
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

In this project, we will A) track the functioning of a collection of potential neurobiological targets for depression over time, B) examine how fluctuations in the functioning of those targets relates to real-world functioning, and C) in a subset of the sample, determine how the functioning in those targets is altered by a single dose of ketamine.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 15
• Est. completion date: August 15, 2023
• Est. primary completion date: July 15, 2023
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 60 Years

Eligibility

Inclusion Criteria:

All participants will:

1. be between the ages of 18 and 60 years,

2. score = 14 on the Hamilton Depression Rating Scale (Ham-D)

3. possess a level of understanding sufficient to agree to all tests and examinations required by the protocol and must sign an informed consent document Exclusion Criteria:

All participants:

1. Presence of lifetime bipolar, psychotic, or autism spectrum; current problematic substance use (e.g., ongoing moderate-to-severe substance use disorder);

2. Failure to meet standard MRI inclusion criteria: those who have cardiac pacemakers, neural pacemakers, cochlear implants, metal braces, or other non-MRI-compatible metal objects in their body. History of significant injury or surgery to the brain or spinal cord that would impair interpretation of results.

3. Acute suicidality or other psychiatric crises requiring treatment escalation. We will use the Columbia Suicide Severity Rating Scale (CSSRS) as both an initial exclusion criteria (CSSRS "Baseline/Screening" Version for past 1month period) and as grounds for rescue/removal (CSSRS "Since Last Visit" form). The CSSRS will be administered using a paper form by an experienced and thoroughly trained clinical assessor on the study team. Subjects with CSSRS suicide ideation scores scored "yes" on items 4 (active suicidal ideation with some intent to act) and/or 5 (active suicidal ideation with specific plan and intent) will be excluded from the study, and if enrolled, will be exited from the study and referred immediately to the nearest emergency mental health facility for additional thorough assessment and appropriate treatment referral.

4. Changes made to treatment regimen within 4 weeks of baseline assessment.

5. Reading level <6th grade as per patient self-report.

6. Patients who have received ECT in the past 2 months prior to Screening.

Ketamine phase subsample additional exclusion criteria:

1. Patients currently taking any psychotropic medication.

2. Lifetime recreational ketamine or PCP use

3. Current pregnancy or breastfeeding

4. For ketamine phase entry, patients must be reasonable medical candidates for ketamine infusion, as determined by a physician co-investigator. Serious, unstable medical illnesses including respiratory [obstructive sleep apnea, or history of difficulty with airway management during previous anesthetics], cardiovascular [including ischemic heart disease and uncontrolled hypertension], and neurologic [including history of severe head injury] will be exclusions.

5. Clinically significant abnormal findings of laboratory parameters [including urine toxicology screen for drugs of abuse], physical examination, or ECG.

6. Uncontrolled or poorly controlled hypertension, as determined by a physician co-investigator's review of vitals collected during screening and any other relevant medical history/records.

7. Patients with one or more seizures without a clear and resolved etiology.

8. Patients starting hormonal treatment (e.g., estrogen) in the 3 months prior to Screening.

9. Past intolerance or hypersensitivity to ketamine.

10. Patients taking medications with known activity at the NMDA or AMPA glutamate receptor [e.g., riluzole, amantadine, lamotrigine, memantine, topiramate, dextromethorphan, Dcycloserine], or the mu-opioid receptor.

11. Patients taking any of the following medications: St John's Wort, theophylline, tramadol, metrizamide.

Related Conditions & MeSH terms

• Depression, Unipolar
• Depressive Disorder

Intervention

Drug:
• Intravenous Ketamine
Single infusion of intravenous racemic ketamine (0.5mg/kg over 40min)

Locations

Country	Name	City	State
United States	Western Psychiatric Institute and Clinic	Pittsburgh	Pennsylvania

Sponsors (1)

Lead Sponsor	Collaborator
Rebecca Price

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Other	Dual probe video task	attentional bias (proportion score) towards sad film clips (range: 0 to +1.0; higher score=greater attention bias towards sad films)	infusion +24 hours (1 day)
Primary	fMRI resting state connectivity	directed connectivity beta weights between default mode, frontoparietal, limbic/affective, and salience networks (larger beta weight = stronger connectivity)	24hrs post-intervention
Secondary	Montgomery-Asberg Depression Rating Scale	Clinician-rated depression (range: 0-60; higher scores = worse outcome)	24hrs post-intervention
Secondary	Montgomery-Asberg Depression Rating Scale	Clinician-rated depression (range: 0-60; higher scores = worse outcome)	5 days post-intervention
Secondary	Montgomery-Asberg Depression Rating Scale	Clinician-rated depression (range: 0-60; higher scores = worse outcome)	12 days post-intervention
Secondary	Hamilton Depression Rating Scale	Clinician-rated depression (range: 0-52; higher scores = worse outcome)	24hrs post-intervention
Secondary	Hamilton Depression Rating Scale	Clinician-rated depression (range: 0-52; higher scores = worse outcome)	5 days post-intervention
Secondary	Hamilton Depression Rating Scale	Clinician-rated depression (range: 0-52; higher scores = worse outcome)	12 days post-intervention
Secondary	Quick Inventory of Depressive Symptoms	Self-reported depression (range: 0-27; higher scores = worse outcome)	24hrs post-intervention
Secondary	Quick Inventory of Depressive Symptoms	Self-reported depression (range: 0-27; higher scores = worse outcome)	5 days post-intervention
Secondary	Quick Inventory of Depressive Symptoms	Self-reported depression (range: 0-27; higher scores = worse outcome)	12 days post-intervention